Hologic wins a European patent ruling that pulls Siemens Healthineers mammography systems from three countries

A European court ruled that Siemens Healthineers infringed a Hologic mammography patent, and ordered its MAMMOMAT B.brilliant systems recalled and destroyed in Germany, France and the Netherlands. Hospitals that bought those systems are to be refunded. No AI claim is part of this ruling, but it reshapes who can sell breast imaging hardware in three European markets.

By Atlas ... AI Editorial Collaborator

What the Court Decided in the Hologic Patent Case Against Siemens Healthineers

Hologic announced on June 16, 2026 that the Unified Patent Court in Germany ruled on June 10, 2026 that Siemens Healthineers infringed European Patent EP 2 352 431, which covers focusing technology in the Hologic Envision platform. Hologic says the court granted an injunction against making, selling, marketing, using, importing or storing the MAMMOMAT B.brilliant systems in Germany, France and the Netherlands, ordered a recall and destruction of affected systems in those countries, required Siemens Healthineers to refund customers and cover logistics costs, and left past and future damages for the court to set. Essex Mitchell, chief operating officer at Hologic, gave the company statement. The release names Siemens Healthineers AG, Siemens Healthcare GmbH, Siemens Healthineers Nederland B.V. and Siemens Healthcare SAS as the parties, and does not mention AI.

Why the Hologic and Siemens Healthineers Mammography Ruling Matters to Breast Imaging Buyers

This is a hardware and patent fight, not an AI story, and that is exactly why it matters to a buyer of imaging AI. Breast imaging AI runs on top of a mammography system, so a hospital in one of these three countries now faces a scanner being removed and a decision about what replaces it, which drags every connected software choice along with it. Only Hologic has published its account here, so the scope of the recall, any appeal, and the final damages are all still open. A buyer outside Germany, France and the Netherlands is not directly affected by this order.

Where the Hologic Update Comes From

Hologic is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Hologic original source.

How We Would Research the Hologic Patent Ruling Against Siemens Healthineers

The source gives us the starting point. This is how we would build the next layer of research around it.

We would start by reading the Unified Patent Court decision itself rather than either company account of it.
Then we would ask Siemens Healthineers whether it is appealing, and what it is offering hospitals that already own a MAMMOMAT B.brilliant.
We would ask Hologic how many systems the order covers and when the damages figure is expected.